Skip to content
HowShorted

Immunome, Inc. short interest in 2022

In 2022, Immunome, Inc.'s disclosed short interest ran from 1.82% of shares outstanding on 14 Jan 2022 to 0.43% on 30 Dec 2022, a change of -1.39 percentage points. The year's high was 1.82% on 14 Jan 2022 and its low 0.32% on 15 Aug 2022, averaging 0.70% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 7.83 days on 31 Oct 2022. Full history: Immunome, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Immunome, Inc. in 2022

2022 in figures

Start of year
1.82% (14 Jan 2022)
End of year
0.43% (30 Dec 2022)
Change
-1.39 pp
High
1.82% (14 Jan 2022)
Low
0.32% (15 Aug 2022)
Average
0.70%
Highest days to cover
7.83 (31 Oct 2022)
SEC filings marked
8

Every report in 2022

Immunome, Inc. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 20221.82%5.43
31 Jan 20221.32%1.94
15 Feb 20221.09%3.75
28 Feb 20221.14%5.41
15 Mar 20221.09%2.25
31 Mar 20221.27%1.2510-K filed, results (8-K)
14 Apr 20220.66%1.30
29 Apr 20221.16%1.00
13 May 20220.58%1.4910-Q filed, results (8-K)
31 May 20220.69%1.28
15 Jun 20220.41%1.67
30 Jun 20220.46%1.00
15 Jul 20220.43%2.24
29 Jul 20220.38%2.12
15 Aug 20220.32%1.0010-Q filed, results (8-K)
31 Aug 20220.32%1.12
15 Sep 20220.35%1.55
30 Sep 20220.38%2.95
14 Oct 20220.35%5.48
31 Oct 20220.38%7.83
15 Nov 20220.55%4.2510-Q filed, results (8-K)
30 Nov 20220.63%3.45
15 Dec 20220.50%2.54
30 Dec 20220.43%1.61

See also: Immunome, Inc.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.